REFERENCES
A French observational study describing the use of human polyvalent
immunoglobulins in hematological malignancy- associated secondary
immunodeficiency, Benbrahim et al.
Use of intravenous immunoglobulin in pediatric practice, Zülfikar et al.
Treatments for hematologic malignancies in contrast to those for solid
cancers are associated with reduced red cell alloimmunization, Evers et
al.
Red cell alloimmunization is associated with development of
autoantibodies and increased red cell transfusion requirements in
myelodysplastic syndrome, Signal et al.
American Society of Hematology 2019 guidelines for immune
thrombocytopenia, Neunert et al.
Autoimmune Complications in Chronic Lymphocytic Leukemia (CLL), Zent et
al.
Current clinical practice and challenges in the management of secondary
immunodeficiency in hematological malignancies Il‐Kang Na
Dhalla F, Lucas M, Schuh A, et al. Antibody deficiency secondary to
chronic lymphocytic leukemia: should patients be treated with
prophylactic replacement immunoglobulin? J Clin Immunol.
2014;34(3):277–282.
Forconi F, Moss P. Perturbation of the normal immune system in patients
with CLL. Blood. 2015;126(5):573–581.
Wadhwa
PD, Morrison VA. Infectious complications of chronic lymphocytic
leukemia. Semin Oncol 2006; 33:240.
Svensson
T1, Höglund
M, Cherif
H. Clinical significance of serum immunoglobulin G subclass deficiency
in patients with chronic lymphocytic leukemia.
Scand J Infect
Dis. 2013 Jul;45(7):537-42. doi: 10.3109/00365548.2013.769279. Epub
2013 Feb 21.
Best
OG, Crassini
K, Freeman
JA, Mulligan
SP; CLL Australian
Research Consortium The clinical significance
of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency
in patients with chronic lymphocytic leukaemia (CLL).
Scand J Infect
Dis. 2013 Sep;45(9):729. doi: 10.3109/00365548.2013.809477. Epub 2013
Jul 5.
Andrea V, Nicolo C,Francesco C, Silvia İ, Renato Z, Francesco P,
Gianpietro S, Livio T, and Carlo A. Clinical profile associated with
infections in patients with chronic lymphocytic leukaemia. Protective
role of immunglobulin in replacement therapy. Haematologica.2015 Dec;
100(12):E515-E-518.
DOİ 10.3324/haematol.2015.126763.
Rozman C, Montserrat E, Viñolas N. Serum immunoglobulins in B-chronic
lymphocytic leukemia. Natural history and prognostic significance.
Cancer 1988;61(2):279-283.
Freeman JA,Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han
P,Stevenson W, Mulligan SP. Immunoglobulin G subclass deficiency and
infection risk in 150 patients with chronic lymphocytic leukemia. Leuk
Lymphoma. 2013 Jan;54(1):99-104. doi: 10.3109/10428194.2012.706285. Epub
2012 Sep 8.
Parikh
SA, Leis
JF, Chaffee
KG, Call
TG, Hanson
CA, Ding
W, Chanan-Khan
AA, Bowen
D, Conte
M, Schwager
S, Slager
SL, Van
Dyke
DL, Jelinek
DF, Kay
NE, Shanafelt
TD. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic
leukemia: Natural history, clinical correlates, and
outcomes.Cancer. 2015
Sep 1;121(17):2883-91. doi: 10.1002/cncr.29438. Epub 2015 Apr 30.
Davey FR, Kurec AS, Tomar RH, Smith JR. Serum immunoglobulins and
lymphocyte subsets in chronic lymphocytic leukemia. Am J Clin
Pathol . 1987;87:60-65.
Shvidel L, Tadmor T, Braester A, et al. Serum immunoglobulin levels at
diagnosis have no prognostic significance in stage A chronic lymphocytic
leukemia: a study of 1113 cases from the Israeli CLL Study
Group. Eur J Haematol . 2014;93:29-33.
Levy
R, Mahévas M, Galicier L, et al. Profound symptomatic
hypogammaglobulinemia: a rare late complication after rituximab
treatment for immune thrombocytopenia. Report of 3 cases and systematic
review of the literature. Autoimmun Rev 2014; 13:1055.
Fernández
Romero
DS1, Torre
MG, Larrauri
BJ, Malbrán
E, Juri
MC, Malbrán
A.[Rituximab
and hypogammaglobulinemia].Medicina
(B Aires). 2015;75(5):319-23.
K:
Roberts
DM1, Jones
RB2, Smith
RM2, Alberici
F3,et al. Rituximab-associated hypogammaglobulinemia:
incidence, predictors and outcomes in patients with multi-system
autoimmune disease.J
Autoimmun. 2015 Feb;57:60-5.)
Casulo
C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in
patients receiving rituximab and the use of intravenous immunoglobulin
for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13:106.
Makatsori
M, Kiani-Alikhan S, Manson AL, et al. Hypogammaglobulinaemia after
rituximab treatment-incidence and outcomes. QJM 2014; 107:821.
Stiegler G, Sperr W, Lorber C, et al. Red cell antibodies in frequently
transfused patients with myelodysplastic syndrome. Ann Hematol.
2001;80(6):330-333.
Sanz C, Nomdedeu M, Belkaid M, et al. Red blood cell alloimmunization in
transfused patients with myelodysplastic syndrome or chronic
myelomonocytic leukemia. Transfusion. 2013;53(4):710-715.
Novaretti MC, Sopelete CR, Velloso ER, et al. Immunohematological
findings in myelodysplastic syndrome. Acta Haematol. 2001;105(1):1-6.
Prevention and management of transfusioninduced alloimmunization:
current perspectives Barbara Hauck-Dlimi